Research programme: Nck protein inhibitors - Artax Biopharma
Latest Information Update: 28 Oct 2019
At a glance
- Originator Artax Biopharma
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Nck protein inhibitors; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders